卫功宏

  • 教育经历

  • 工作经历

  • 获得人才项目

  • 获得奖项

  • 研究方向

  • 科研项目

  • 课程讲授

  • 学术兼职

  • 代表性论著

  • 1996.09—2000.07  安徽师范大学生命科学学院本科

  • 2000.09—2003.07  首都师范大学生命科学学院硕士

  • 2003.08—2006.09  北京协和医学院基础学院博士

  • 2006.10—2011.10  芬兰赫尔辛基大学医学院博士后

  • 2011.11—2019.11  芬兰奥卢大学医学院青年研究员、副教授、教授

  • 2014.9—2019.8    芬兰科学院研究员

  • 2016.9—2019.11Cancer Genomics Unit Leader

  • 2019.11—至今     复旦大学基础医学院特聘教授

  • 2021.10—至今     复旦大学基础医学院生物化学与分子生物学系主任

  • 2019,国家重点联系专家

  • 2019,上海市海外高层次人才

  • 2019,Medix Prize

  • 2018,Biocenter Oulu Discovery of the Year

  • 2017,Excellent doctoral thesis award of University of Oulu Medical School

  • 2016,Biocenter Oulu Discovery of the Year

  • 2015,Medix Prize

  • 2014,Biocenter Oulu Discovery of the Year

  • 2009,国际生化大会(IUBMB&FAOBMB)Pfizer最佳壁报奖

  • 2006,北京协和医学院优秀研究生(基础学院)

  • 基因表达调控与人类疾病

  • 医学遗传学与基因组学

  • 表观遗传与系统生物学

  • 2021,国家自然科学基金委面上项目,主持

  • 临床医学专业六年制MBBS全英文授课《Biochemistry》

  • 预防班专业五年制授课《生物化学》

  • 2021-2022 Frontiers in Oncology Special Issue Guest Editor

  • 2018-今 Asian Journala of UrologyAssociate Editor

  • 2018-今 Scientific ReportsEBM

  • 2018-今Society of Chinese Bioscientists in America (SCBA) Life International Membership

  • 2015-2019Finnish Connective Tissue Society Membership

  1. Nikolaos Giannareas1#, Qin Zhang1#, Xiayun Yang1#, Rong Na2#, Yijun Tian3, Yuehong Yang1, Xiaohao Ruan4, Da Huang4, Xiaoqun Yang5, Chaofu Wang5, Peng Zhang6, Aki Manninen1, Liang Wang4, Gong-Hong Wei*. Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG. Nature Communications. accepted

  2. Zhang N, Huang D, Jiang G, Chen S, Ruan X, Chen H, Huang J, Liu A, Zhang W, Lin X, Wu Y, Zhang Q, Li J, Tsu JH*, Wei GH*, Na R*. Genome-Wide 3'-UTR Single Nucleotide Polymorphism Association Study Identifies Significant Prostate Cancer Risk-Associated Functional Loci at 8p21.2 in Chinese Population. Adv Sci(Weinh). 2022 Aug;9(23):e2201420.

  3. Chen Y, Zhang P, Liao J, Cheng J, Zhang Q, Li T, Zhang H, Jiang Y, Zhang F, Zeng Y, Mo L, Yan H, Liu D, Zhang Q, Zou C*, Wei GH*, Mo Z*. Single-cell transcriptomics reveals cell type diversity of human prostate. J Genet Genomics. 2022 Apr 6:S1673-8527(22)00090-X (cover story).

  4. Tian P#, Zhong M#, Wei GH*. Mechanistic insights into genetic susceptibility to prostate cancer. Cancer Letters. 2021 Sep 22; 522:155-163.

  5. Ahmed M#, Soares F#, Xia JH#, Yang Y, Li J, Guo H, Su P, Tian Y, Lee JH, Wang M, Akhtar N, Houlahan KE, Bosch A, Zhou S, Mazrooei P, Hua J, Chen S, Petricca J, Zeng Y, Davies A, Fraser M, Quigley DA, Feng F, Boutros PC, Lupien M, Zoubeidi A, Wang L, Walsh MJ, Wang T, Ren S*, Wei GH*, He HH*. CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer, Nature Communications. 2021 Mar 19; 12(1):1781.

  6. Gao P#, Xia JH#, Sipeky C, Dong XM, Zhang Q, Yang Y, Zhang P, Cruz SP, Zhang K, Zhu J, Lee HM, Suleman S, Giannareas N, Liu S; PRACTICAL Consortium, Tammela TLJ, Auvinen A, Wang X, Huang Q, Wang L, Manninen A, Vaarala MH, Wang L, Schleutker J, Wei GH*. Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. Cell. 2018. 174:576-589.

    Previewed in Bulger M. Changing the Guard at a Prostate Cancer SNP. Cell. 174:501-502, 2018
    Highlighted in Bradley C. Mechanistic insights into a non-coding risk SNP. Nature ReviewsUrology15:655, 2018
    Invited author's views: Xia JH & Wei GH. Oncogenic regulatory circuits driven by 19q13 rs11672691 underlies prostate cancer aggressiveness. Molecular & Cellular Oncology. 5(6):e1516451. 2018

  7. Huang Q#, Whitington T#, Gao P, Lindberg JF, Yang Y, Sun J, Väisänen MR, Szulkin R, Annala M, Yan J, Egevad LA, Zhang K, Lin R, Jolma A, Nykter M, Manninen A, Wiklund F, Vaarala MH, Visakorpi T, Xu J, Taipale J*, Wei GH*. A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. Nature Genetics. 2014. 46:126-135.

    Previewed in HOXB13, RFX6 and prostate cancer risk. Nature Genetics. 46:94-95, 2014

    Highlighted in Prostate cancer: HOXB13 and a SNP collaborate to increase risk. Nature Reviews Urology. 11:64, 2014
    Research Watch A Prostate Cancer–Associated SNP Increases HOXB13 Binding. Cancer Discovery4:268, 2014
    Recommended by Faculty of 1000: ★★ Very Good, good for teaching, new finding. In F1000Prime, 27 Jan 2014; DOI: 10.3410/f.718228195.793490008
    News in JNCI: Journal of the National Cancer Institute, 2014
    Eturauhassyöpään johtava geenimuutos löytyi Oulussa. HELSINGIN SANOMAT Jan 10 2014

  8. Whitington T#, Gao P#, Song W, Ross-Adams H, Lamb AD, Yang Y, Svezia I, Klevebring D, Mills IG, Karlsson R, Halim S, Dunning MJ, Egevad L, Warren AY, Neal DE, Grönberg H, Lindberg J, Wei GH (joint supervision), Wiklund F. Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nature Genetics. 2016. 48:387-397.

    Research Watch Prostate Cancer Risk Loci Are Associated with Gene Regulatory Mechanisms. Cancer Discovery 6:OF13, 2016

  9. Zhang P#, Xia J#, Zhu J, Gao P, Tian YJ, Du M, Guo CY, Suleman S, Zhang Q, Kohli M, Tillmans L, Thibodeau SN, French AJ, Cerhan JR, Wang LD*, Wei GH*, Wang L*. High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing. Nature Communications. 2018. 9, 2022.

  10. Sipeky C#, Gao P#, Zhang Q, Wang L, Ettala O, Talala K, Tammela TL, Auvinen A, Wiklund F, Wei GH*, Schleutker J*. Synergistic interaction of HOXB13 and CIP2A predispose to aggressive prostate cancer. Clinical Cancer Research. 2018. 15;24(24):6265-6276.